stockrowThe Cooper Companies, Inc.
COO Healthcare Medical Instruments & Supplies
The Cooper Companies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $4.1 billion, up 5.06% from fiscal 2024.
- Revenue
- +0.56%
- EPS
- +357.1%
- Free cash flow
- +66.0%
- Total debt
- +2.66%
Quarter to July 2026, against a year earlier
Follow COO
Alert me
The Cooper Companies, Inc. (COO) EPS (diluted)
The Cooper Companies, Inc.'s EPS (diluted) for fiscal 2025 was $1.87, unchanged from fiscal 2024. Over the twelve months to 31 July 2026 it was $2.93. Over the past ten years it has ranged from $0.70 (fiscal 2018) to $14.79 (fiscal 2021); the current reading is higher than 55% of that period. The Cooper Companies, Inc. ranks 10th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.87 | (4.59%) |
| FY2024 | $1.96 | 32.66% |
| FY2023 | $1.48 | (23.84%) |
| FY2022 | $1.94 | (86.88%) |
| FY2021 | $14.79 | 1,129.94% |
| FY2020 | $1.20 | (48.45%) |
| FY2019 | $2.33 | 232.03% |
| FY2018 | $0.70 | (62.63%) |
| FY2017 | $1.88 | 34.53% |
| FY2016 | $1.40 | 35.02% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jul 2026 | $2.24 | — |
| Apr 2026 | −$0.40 | — |
| Jan 2026 | $0.66 | 53.49% |
| Oct 2025 | $0.43 | (12.24%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALGN Align Technology, Inc. compare | $6.87 |
| ATR AptarGroup, Inc. compare | $4.12 |
| COO The Cooper Companies, Inc. | $2.93 |
| SOLV Solventum Corporation compare | $0.89 |
| AVTR Avantor, Inc. compare | $0.50 |
| RGEN Repligen Corporation compare | −$0.21 |
| BLCO Bausch + Lomb Corporation compare | −$0.30 |
| BAX Baxter International Inc. compare | −$1.41 |
| TFX Teleflex Incorporated compare | −$23.29 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on COO
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement